Sanofi Joins mRNA COVID-19 Club With Translate Tie-Up
Two-Pronged Approach For A Coronavirus Vaccine
The French drugmaker has joined the likes of Moderna, BioNTech and CureVac in advancing an mRNA vaccine against the virus that causes COVID-19 that could take the fraction of the time to develop compared with the old egg- and cell-based technology.
You may also be interested in...
Paul Hudson has been at the helm of Sanofi for just nine months, but for the last few days his comments about which country will be first in line for the firm's coronavirus vaccines will have reminded him that the Gallic culture runs deep.
Plus: Lilly unveils Olumiant COVID-19 study, Samsung and Vir to collaborate on antibody, Korean industry asks for government assistance.
The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.